Filtered By:
Specialty: Endocrinology
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 2159 results found since Jan 2013.
Admission hyperglycemia, stroke subtypes, outcomes in acute ischemic stroke
Whether admission hyperglycemia is differentially associated with early vascular outcomes in acute ischemic stroke(AIS) depending on stroke subtype has been incompletely delineated.
Source: Diabetes Research and Clinical Practice - January 11, 2023 Category: Endocrinology Authors: Joon-Tae Kim, Ji Sung Lee, Beom Joon Kim, Jihoon Kang, Keon-Joo Lee, Jong-Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Tai Hwan Park, Kyung Bok Lee, Jun Lee, Keun-Sik Hong, Yong-Jin Cho, Hong-Kyun Park, Byung-Chul Lee, Kyun Source Type: research
Elevated stress hyperglycemia and the presence of intracranial artery stenosis increase the risk of recurrent stroke
ConclusionsSHR represents a better biomarker to predict the risk of stroke recurrence in patients with ICAS than FPG and HbA1c regardless of previous diabetes mellitus.Trial registrationhttps://www.chictr.org.cn/showproj.aspx?proj=125817; Identifier, [ChiCTR2100046958].
Source: Frontiers in Endocrinology - January 9, 2023 Category: Endocrinology Source Type: research
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research
Association of urinary nitrate with diabetes complication and disease-specific mortality among adults with hyperglycemia
CONCLUSIONS: Higher urinary nitrate is associated with lower risk of congestive heart failure and diabetic nephropathy, and lower risk of all-cause, CVD, and diabetes mortalities. These findings indicated that inorganic nitrate supplementation can be considered as a supplementary treatment for people with hyperglycemia.PMID:36576885 | DOI:10.1210/clinem/dgac741
Source: The Journal of Clinical Endocrinology and Metabolism - December 28, 2022 Category: Endocrinology Authors: Wenbo Jiang Jia Zhang Ruiming Yang Xinyi Sun Huanyu Wu Jiacheng Zhang Siyao Liu Changhao Sun Lifang Ma Tianshu Han Wei Wei Source Type: research
Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients with Type 2 Diabetes
J Clin Endocrinol Metab. 2022 Dec 27:dgac750. doi: 10.1210/clinem/dgac750. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPIs) are widely used drugs for gastric-acid-related diseases, which may have an impact on the gut microbiome. We aimed to evaluate the associations of PPI use with risks of cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D).METHODS: We analysed the associations of PPI use with risks of coronary artery disease (CAD), myocardial infarction (MI), heart failure (HF), stroke, and all-cause mortality in 19,229 adults with T2D using data from the UK ...
Source: The Journal of Clinical Endocrinology and Metabolism - December 27, 2022 Category: Endocrinology Authors: Tingting Geng Jun-Xiang Chen Yan-Feng Zhou Qi Lu Zhenzhen Wan Liegang Liu An Pan Gang Liu Source Type: research
Disparities in Adoption of New Diabetic Therapies with Cardiovascular Benefits
Cardiovascular disease remains the most common cause of death among patients with diabetes [1 –3]. Two recently approved classes of medications for Type 2 diabetes mellitus (T2DM) reduce the risk of cardiovascular events. Glucagon-like peptide-1 agonists (GLP1RA) reduce death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke in patients T2DM[5–10]. Sodium-gl ucose co-transporter 2 inhibitors (SGLT2i) reduce heart failure events by 27% to 39% and decrease the frequency of worsening renal disease by 39% compared to placebo in patients with T2DM.
Source: Diabetes Research and Clinical Practice - December 26, 2022 Category: Endocrinology Authors: Elena C. Vasti, Marina Basina, Jamie Calma, David J. Maron, Fatima Rodriguez, Alexander T. Sandhu Source Type: research
Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients
ConclusionA12 containing genotypes and A12 allele are not associated with IR, diabetes and risk of IS development, however, significant higher BMI were observed in A12 allele carriers in the studied patients with diabetes as well as those with IS.
Source: Journal of Diabetes and Metabolic Disorders - December 22, 2022 Category: Endocrinology Source Type: research
Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis
ConclusionsIn these T2DM patients with ACS, a significantly lower risk of major adverse cardiovascular events including all-cause mortality was observed in the ticagrelor group compared with the clopidogrel group. However, T2DM patients who were assigned to ticagrelor showed a significantly higher minor bleeding risk. Larger clinical trials should be able to confirm these hypotheses.
Source: Diabetes Therapy - December 21, 2022 Category: Endocrinology Source Type: research
